Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
LINKER-MM3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05730036 ↗
- Recruiting
- Regeneron Pharmaceuticals
- Standard
We haven't built an HCP commentary report on LINKER-MM3 (linvoseltamab in relapsed/refractory multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LINKER-MM3 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 5 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- Linvoseltamab; Elotuzumab; Pomalidomide; Dexamethasone
- Arms
- Linvoseltamab · Experimental
- Elotuzumab/Pomalidomide/Dexamethasone (EPd) · Active comparator
- Enrollment
- 410 (estimated)
- Primary outcomes
- Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participants
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 18, 2023
- Primary completion
- Apr 19, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT05730036 · updated Oct 7, 2026